| II-18 Yin Edwards Exposure-safety analysis of Tovorafenib (DAY101), an investigational oral pan-RAF kinase inhibitor, in oncology patients with solid tumors Wednesday 15:10-16:40 |
| II-18 Yin Edwards Exposure-safety analysis of Tovorafenib (DAY101), an investigational oral pan-RAF kinase inhibitor, in oncology patients with solid tumors Wednesday 15:10-16:40 |